MiCAN Technologies Inc.

Booth 1353
Kyoto, Japan
We are a startup venture established in 2016. Our main product utilizes regenerative medical technologies such as iPS to produce immortalized immature dendritic cells (Mylc cells). These cells express conventional receptors such as Toll-like receptors. Therefore these cells can perform normal cytokine production.
We provide high-quality immature blood cells developed for various evaluations of functional materials for pharmaceuticals, infectious diseases, cosmetics, and foods. You could evaluate the efficacy and safety of drug candidates and functional materials more accurately, efficiently and quickly at lower cost than ever. If you have problem with cell-based assays, please contact us.